Incretin Atlas › Trials › ZUPREME-2 (obesity + T2D)
ZUPREME-2 (obesity + T2D)
Petrelintide · t2d
Design
- Molecule(s)
- Petrelintide
- Population
- t2d
- Phase
- 2
- Duration
- 28 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| petrelintide, highest dose | t2d | 28 | — | −9.2 % vs −2.0 % Δ −7.2 pp | — | −0.7 vs +0.2 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- petrelintide, highest dose: Topline release: best of three dose arms ("up to"); doses and per-arm results not yet disclosed.
Verbatim quotes from the source (2)
- petrelintide, highest dose · weight_eff · company announcement
Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
- petrelintide, highest dose · hba1c · company announcement
At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: ZUPREME-2 (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.